Sensible Medical Innovations
Noninvasive Lung Fluid Monitoring and Management
Company Overview
Snapshot
Founded in June 2007 by Amir Ronen, Amir Saroka, Shlomi Bergida, Nadav Mizrahi, and Dan Rappaport, Sensible Medical Innovations operates with 11–50 employees. The company has raised $37.56 million across five funding rounds from four investors. In September 2025, its ReDS Pro System was contracted for inclusion in the Federal Supply Schedule for VA medical facilities in the US.
Business overview
Sensible Medical Innovations develops medical radar technology, ReDS, derived from defense industry 'see-through-walls' technology. The company's core product, the ReDS system, is designed for noninvasive monitoring and management of patients with fluid management problems, particularly those with heart failure or recovering from coronary artery disease events. It serves healthcare providers in hospitals, hospital-type facilities, and home environments, operating within the Health Tech & Life Sciences sector, specifically in Digital Healthcare and Patient Remote Monitoring.
Strategic signal
The inclusion of Sensible Medical's ReDS Pro System in the Federal Supply Schedule in September 2025 marks a significant milestone, making its technology available to VA medical facilities across the US. This development signals strong validation of the ReDS system's clinical utility and market readiness, indicating a substantial expansion opportunity within the federal healthcare system and reinforcing its position as a key player in noninvasive patient monitoring.
Log in to access full profile ›Company Intelligence Q&A
- What is Sensible Medical Innovations' primary technology?
- Sensible Medical Innovations' primary technology is the ReDS medical radar, which enables noninvasive monitoring of lung fluid. This technology originated from defense industry applications for 'see-through-walls' capabilities.
- What was a key market expansion for Sensible Medical Innovations in 2025?
- In September 2025, Sensible Medical Innovations' ReDS™ Pro System was contracted for inclusion in the Federal Supply Schedule (FSS), making it available to VA medical facilities in the US.
- When did Sensible Medical Innovations license its ReDS technology to Bayer?
- Sensible Medical Innovations licensed its ReDS™ technology to Bayer in May 2019.
- What was a notable investment in Sensible Medical Innovations in 2019?
- In January 2019, Medicure Inc. invested in Sensible Medical Innovations to market the ReDS system.
- When did Sensible Medical Innovations receive FDA clearance for its monitor?
- Sensible Medical Innovations received FDA 510K clearance for its non-invasive thoracic fluid status monitor in August 2015.